Astrazeneca Jab
- All
- News
- Videos
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
European Union Drugs Regulator Approves AstraZeneca Jab As Covid Booster
AstraZeneca's Covid jab has won approval for use as a booster or third jab in the European Union, the British drugs giant confirmed Monday.
-
EU Drug Watchdog Approves AstraZeneca's Covid Prevention Jab 'Evusheld'
The EU's drug watchdog on Thursday recommended for approval AstraZeneca's Covid-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
EU Commissioner Hopeful People Vaccinated With AstraZeneca Can Enter US
While Washington has not authorized the AstraZeneca vaccine against Covid-19, a European commissioner on Monday expressed hope that travelers from the continent inoculated with the jab will soon be able to enter the United States.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Thailand To Mix Sinovac, AstraZeneca Jabs "To Boost Protection Against Delta Variant"
Thailand's immunisation strategy against the coronavirus will see a shot of AstraZeneca's viral vector vaccine administered after one dose of Sinovac's vaccine, its health minister said on Monday.
-
Germany Recommends Vaccine Switch After AstraZeneca First Shot
Germany's vaccine committee on Thursday recommended that everyone who received an AstraZeneca first dose switch to BioNTech-Pfizer or Moderna jabs for better protection against the coronavirus, including against the Delta variant.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
Australia Restricts AstraZeneca Vaccine For All Under 60 Due to Clotting Concerns
Australia recommended that AstraZeneca's Covid-19 jab should not be given to people under 60 on Thursday, a fresh blow to the country's glacial vaccine rollout.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
AstraZeneca Covid Jab Linked To Higher Risk Of Rare Blood Clot, Finds Study
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said on Thursday.
-
European Union Drugs Regulator Approves AstraZeneca Jab As Covid Booster
AstraZeneca's Covid jab has won approval for use as a booster or third jab in the European Union, the British drugs giant confirmed Monday.
-
EU Drug Watchdog Approves AstraZeneca's Covid Prevention Jab 'Evusheld'
The EU's drug watchdog on Thursday recommended for approval AstraZeneca's Covid-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
EU Commissioner Hopeful People Vaccinated With AstraZeneca Can Enter US
While Washington has not authorized the AstraZeneca vaccine against Covid-19, a European commissioner on Monday expressed hope that travelers from the continent inoculated with the jab will soon be able to enter the United States.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Thailand To Mix Sinovac, AstraZeneca Jabs "To Boost Protection Against Delta Variant"
Thailand's immunisation strategy against the coronavirus will see a shot of AstraZeneca's viral vector vaccine administered after one dose of Sinovac's vaccine, its health minister said on Monday.
-
Germany Recommends Vaccine Switch After AstraZeneca First Shot
Germany's vaccine committee on Thursday recommended that everyone who received an AstraZeneca first dose switch to BioNTech-Pfizer or Moderna jabs for better protection against the coronavirus, including against the Delta variant.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
Australia Restricts AstraZeneca Vaccine For All Under 60 Due to Clotting Concerns
Australia recommended that AstraZeneca's Covid-19 jab should not be given to people under 60 on Thursday, a fresh blow to the country's glacial vaccine rollout.
